Tff Pharmaceuticals, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
TFF Pharmaceuticals' stockholders voted to approve the dissolution of the company at a special meeting held on March 3, 2025.
TFF Pharmaceuticals issued 4,443,926 special shares to its CEO to ensure a quorum at the adjourned special meeting to vote on the company's dissolution.
TFF Pharmaceuticals has received a delisting notification from Nasdaq due to its plan of dissolution and concerns about its ability to maintain listing requirements.
TFF Pharmaceuticals has announced it will terminate its employees and wind down operations, appointing Craig R. Jalbert as CEO, President, CFO, Treasurer, and Secretary.